Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986442 + Nivolumab in Advanced Solid Tumors and NSCLC
NCT05543629Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2022
- Primary completion
- Sep 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label trial of AGEN1777 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), gastric cancer (GC) and 1 more (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Adverse Events, Number of Participants With Serious Adverse Events and 2 more. Started Oct 2022; status: terminated.
02
Drugs
AGEN1777
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)gastric cancer (GC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05543629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543629.